Almirall May Pull Sativex After German Arbitration Board Pricing Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
Germany’s reimbursement arbitration board has proposed a rock bottom price for GW Pharmaceuticals/Almirall’s cannabinoid preparation Sativex (nabiximols) for MS-related spasticity.
You may also be interested in...
Germany’s Pricing Revolution: Why The World Should Be Watching
Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.